Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 151
Filtrar
1.
Pharm Dev Technol ; 29(6): 639-647, 2024 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-38980085

RESUMO

Doxepin, a Class-I Biopharmaceutics Drug Disposition Classification System (BDDCS) drug, exhibits poor bioavailability due to extensive first-pass metabolism. This research focuses on enhancing the delivery of doxepin by formulating nanostructured lipid carriers (NLCs) through the utilization of the Box-Behnken Design methodology. These optimized NLCs are intended for intranasal administration, with the ultimate goal of improving nose-to-brain drug delivery. NLCs were formulated using a high-speed homogenization technique. The optimized batch had a small particle size (75.80 ± 5.48 nm, PDI = 0.286), high entrapment efficiency (94.10 ± 0.16%), and sustained ex vivo release (82.25 ± 4.61% at 24 h). Characterization studies confirmed the conversion of doxepin from a crystalline to an amorphous state with uniform distribution in the lipid matrix. In vivo pharmacokinetic studies in rats showed significantly higher doxepin concentration in the brain tissue (Cmax = 16.77 µg/g, tmax = 30 min) after intranasal administration compared to intravenous administration (Cmax = 2.53 µg/g, tmax = 6 h). High-drug targeting efficiency (DTE = 284.3%) and direct transport percentage (DTP = 64.8%) suggested direct penetration of NLCs in the brain via olfactory and trigeminal pathways. In conclusion, the study highlights the potential of NLCs to improve the bioavailability of doxepin through nose-to-brain delivery and thereby potentially enable the treatment of neurological disorders.


Assuntos
Administração Intranasal , Disponibilidade Biológica , Encéfalo , Doxepina , Portadores de Fármacos , Lipídeos , Nanoestruturas , Animais , Doxepina/farmacocinética , Doxepina/administração & dosagem , Encéfalo/metabolismo , Lipídeos/química , Portadores de Fármacos/química , Ratos , Masculino , Nanoestruturas/química , Tamanho da Partícula , Sistemas de Liberação de Medicamentos/métodos , Ratos Sprague-Dawley , Liberação Controlada de Fármacos , Biofarmácia/métodos , Mucosa Nasal/metabolismo
5.
Int J Pharm ; 535(1-2): 393-401, 2018 Jan 15.
Artigo em Inglês | MEDLINE | ID: mdl-29146542

RESUMO

The main purpose of this study was to develop a semisolid mucoadhesive formulation for the non-invasive vaginal administration of doxepin (DOX) for relief of pain derived from the scarring process after surgery. An orafix® platform loading DOX was tested for adequate stability, rheology and vaginal mucoadhesion capacity. The formulation exhibited appropriate pH and was microbiologically stable. The rheological studies confirmed its pseudoplastic and thixotropic nature with prevalence of the elastic behavior component over the viscous one. Appropriate syringeability and spreadability results were also confirmed. Different experiments showed adequate mucoadhesion capacity even in the presence of simulated vaginal fluid. Finally, DOX release, permeation and retention in vaginal mucosa studies were also accomplished with promising results. DOX release kinetics followed the modified Higuchi model and the permeation studies did not render such high values as to suggest potential systemic absorption which could lead to undesirable systemic side effects. Therefore, we can hypostatize that the proposed formulation may assist to fill in the therapeutic gap regarding pure pain relief at local level in vagina.


Assuntos
Analgésicos/administração & dosagem , Doxepina/administração & dosagem , Sistemas de Liberação de Medicamentos , Adesividade , Administração Intravaginal , Analgésicos/química , Animais , Doxepina/química , Liberação Controlada de Fármacos , Estabilidade de Medicamentos , Feminino , Mucosa/química , Dor/tratamento farmacológico , Reologia , Suínos , Vagina , Viscosidade
6.
Am Fam Physician ; 96(1): 29-35, 2017 Jul 01.
Artigo em Inglês | MEDLINE | ID: mdl-28671376

RESUMO

Insomnia accounts for more than 5.5 million visits to family physicians each year. Although behavioral interventions are the mainstay of treatment, pharmacologic therapy may be necessary for some patients. Understanding the risks and benefits of insomnia medications is critical. Controlled-release melatonin and doxepin are recommended as first-line agents in older adults; the so-called z-drugs (zolpidem, eszopiclone, and zaleplon) should be reserved for use if the first-line agents are ineffective. For the general population with difficulty falling asleep, controlled-release melatonin and the z-drugs can be considered. For those who have difficulty staying asleep, low-dose doxepin and the z-drugs should be considered. Benzodiazepines are not recommended because of their high abuse potential and the availability of better alternatives. Although the orexin receptor antagonist suvorexant appears to be relatively effective, it is no more effective than the z-drugs and much more expensive. Sedating antihistamines, antiepileptics, and atypical antipsychotics are not recommended unless they are used primarily to treat another condition. Persons with sleep apnea or chronic lung disease with nocturnal hypoxia should be evaluated by a sleep specialist before sedating medications are prescribed.


Assuntos
Distúrbios do Início e da Manutenção do Sono/tratamento farmacológico , Benzodiazepinas/administração & dosagem , Benzodiazepinas/uso terapêutico , Doxepina/administração & dosagem , Doxepina/uso terapêutico , Humanos , Hipnóticos e Sedativos/administração & dosagem , Hipnóticos e Sedativos/uso terapêutico , Melatonina/administração & dosagem , Melatonina/agonistas , Melatonina/uso terapêutico
7.
Sleep ; 40(7)2017 07 01.
Artigo em Inglês | MEDLINE | ID: mdl-28575467

RESUMO

Study Objectives: To examine and compare the arousability threshold and fall risk upon awakening of doxepin (6 mg) versus zolpidem (10 mg). Methods: A total of 52 healthy adult males were included in a double-blind, placebo-controlled, four-way crossover study. The experimental procedure included four nights with polysomnography in the lab (zolpidem, doxepin, and their respective placebo conditions). Arousability was measured using an auditory awakening threshold delivered at the peak-plasma concentration for the active hypnotics and at matched times for the respective placebo conditions. Fall risk during the night was measured following awakening using the Berg Balance Scale and the Tandem Walk Task. Results: Both arousability and fall risk were lower in the doxepin condition compared to the zolpidem condition. Furthermore, arousability and fall risk for doxepin did not differ significantly from the placebo conditions. A significantly greater proportion of participants in the zolpidem condition (63.5%) did not wake until receiving the loudest tone (110 dB) as compared to the doxepin (17.6%) and placebo conditions (17.3%, 5.8%). Conclusions: Results suggest that zolpidem has greater risks for balance and awakening threshold compared with low-dose doxepin. Future prospective studies should extend results to clinical samples with population-level risk of injury and arousability.


Assuntos
Acidentes por Quedas , Nível de Alerta/efeitos dos fármacos , Doxepina/administração & dosagem , Doxepina/farmacologia , Piridinas/administração & dosagem , Piridinas/farmacologia , Sono/efeitos dos fármacos , Adulto , Nível de Alerta/fisiologia , Estudos Cross-Over , Método Duplo-Cego , Voluntários Saudáveis , Humanos , Hipnóticos e Sedativos/administração & dosagem , Hipnóticos e Sedativos/farmacologia , Masculino , Pessoa de Meia-Idade , Placebos , Polissonografia , Sono/fisiologia , Vigília/efeitos dos fármacos , Vigília/fisiologia , Adulto Jovem , Zolpidem
8.
BMJ Case Rep ; 20172017 May 22.
Artigo em Inglês | MEDLINE | ID: mdl-28536226

RESUMO

A 17-year-old female with recently relapsed acute lymphoblastic leukaemia and a treatment course complicated by rhinocerebral mucormycosis infection developed severe peripheral neuropathy during the treatment for mucormycosis infection. This was felt to be a medication side effect. Her peripheral neuropathy was refractory to many well-established treatments, but ultimately responded dramatically and consistently to a novel therapy, topical doxepin cream (5%). This case report is the first published report of the application of topical doxepin cream for treatment of peripheral neuropathy in a paediatric patient.


Assuntos
Doxepina/administração & dosagem , Doenças do Sistema Nervoso Periférico/induzido quimicamente , Doenças do Sistema Nervoso Periférico/tratamento farmacológico , Administração Tópica , Adolescente , Formas de Dosagem , Feminino , Humanos , Mucormicose/complicações , Mucormicose/tratamento farmacológico , Leucemia-Linfoma Linfoblástico de Células Precursoras/complicações , Índice de Gravidade de Doença
9.
Eur J Pharm Biopharm ; 117: 203-211, 2017 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-28438551

RESUMO

This study describes the development of semisolid formulations containing doxepin (DOX) for pain relief in oral mucositis, frequently related to chemotherapy and/or radiotherapy treatments in patients with head and neck cancer. Chemical permeation enhancers were evaluated and selected according to the results obtained from rheological studies, drug release, and drug permeation and retention through buccal mucosa. Finally, the selected formulation was compared in vivo, with a reference DOX mouthwash, whose clinical efficacy had been previously reported. The obtained findings showed that an orabase® platform loading transcutol® (10%) and menthol (5%) for the buccal vehiculization of DOX exhibited a decreased elastic and viscous behavior improving its application. The main drug release mechanism could be considered as diffusion according to Higuchi model. Obtained DOX permeation rates were considered optimal for an analgesic effect and far below to an antidepressant activity. Similar in vivo plasma concentrations were found for the semisolid formulation and the reference mouthwash. However, DOX amounts retained in the mucosa of animals for the semisolid formulation were higher than the reference, which let us hypostatize even stronger potential local therapeutic effect with additional advantages such as, mucoadhesive properties, absence of alcohol, some degree of freshness, as well as, drug palatability improvement.


Assuntos
Doxepina/metabolismo , Neoplasias de Cabeça e Pescoço/metabolismo , Mucosa Bucal/metabolismo , Antissépticos Bucais/metabolismo , Dor/metabolismo , Estomatite/metabolismo , Animais , Doxepina/administração & dosagem , Doxepina/química , Feminino , Neoplasias de Cabeça e Pescoço/tratamento farmacológico , Antagonistas dos Receptores Histamínicos/administração & dosagem , Antagonistas dos Receptores Histamínicos/química , Antagonistas dos Receptores Histamínicos/metabolismo , Masculino , Mucosa Bucal/efeitos dos fármacos , Antissépticos Bucais/administração & dosagem , Antissépticos Bucais/química , Técnicas de Cultura de Órgãos , Dor/tratamento farmacológico , Estomatite/tratamento farmacológico , Suínos , Resultado do Tratamento
10.
Ther Deliv ; 7(10): 683-689, 2016 10.
Artigo em Inglês | MEDLINE | ID: mdl-27790954

RESUMO

AIM: Doxepin is a traditional tricyclic antidepressant with analgesic and anesthetic properties when applied topically to the mucosa. Doxepin is one approach in treating insomnia and depression in Parkinson's disease. Patients with Parkinson's disease suffer difficulties in swallowing. Therefore, it was the aim of this study to develop a buccal-adhesive delivery system. METHODS: Pectin was modified with cysteine. Stability assays in form of disintegration assay according to the Ph.Eur were performed. Furthermore, bioadhesiveness on buccal mucosa was investigated incorporating the drug doxepin. RESULTS: The adhesiveness was improved 1.4-fold and revealed a sustained release over 3 h. CONCLUSION: Taking these findings into account, the modifications render this designed excipient fruitful for buccal delivery.


Assuntos
Cisteína/química , Doxepina/administração & dosagem , Portadores de Fármacos/administração & dosagem , Portadores de Fármacos/química , Pectinas/química , Adesividade , Administração Bucal , Sobrevivência Celular/efeitos dos fármacos , Células Cultivadas , Doxepina/efeitos adversos , Doxepina/farmacocinética , Liberação Controlada de Fármacos , Estabilidade de Medicamentos , Humanos , Mucosa Bucal/efeitos dos fármacos
11.
Gynecol Endocrinol ; 32(12): 986-990, 2016 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-27345718

RESUMO

Depressive symptoms are very frequent over a lifetime, especially for women. Menopause is a period of higher depressive vulnerability. There are suggestive data that estrogen deficiency may increase the susceptibility for depression. We studied whether a bilateral ovariectomy (OVX) modifies mice behaviors and antidepressant drug effects through tail suspension test (TST). We evaluated behavioral changes at 1 week, 2 weeks, and up to 2 months after OVX. The behavior responses to doxepin, paroxetine, and venlafaxine at 1 week, 2 weeks, and 2 months after OVX were evaluated. No obvious difference was detected on the duration of immobility among control group, sham group, and OVX group in the TST at 1 week and 2 weeks after OVX. But the duration of immobility of OVX group was distinctly longer than that of both control group and sham operation group at 2 months after OVX. At 1 and 2 weeks after OVX, only the antidepressant response to venlafaxine was observed, while response to paroxetine increased 2 months after OVX. Response to antidepressant drugs was strongly modified in OVX mice. The present results suggest that not all antidepressant drugs are appropriate for depression with estrogen deficiency.


Assuntos
Antidepressivos/farmacologia , Comportamento Animal/efeitos dos fármacos , Depressão/tratamento farmacológico , Doxepina/farmacologia , Ovariectomia/efeitos adversos , Paroxetina/farmacologia , Cloridrato de Venlafaxina/farmacologia , Animais , Antidepressivos/administração & dosagem , Depressão/metabolismo , Modelos Animais de Doenças , Doxepina/administração & dosagem , Estrogênios/metabolismo , Feminino , Elevação dos Membros Posteriores , Menopausa/efeitos dos fármacos , Menopausa/metabolismo , Camundongos , Camundongos Endogâmicos ICR , Paroxetina/administração & dosagem , Cloridrato de Venlafaxina/administração & dosagem
12.
BMC Anesthesiol ; 15: 116, 2015 Aug 08.
Artigo em Inglês | MEDLINE | ID: mdl-26253075

RESUMO

BACKGROUND: Many researchers have suggested that the glutamatergic system may be involved in the effects of antidepressant therapies. We investigated the effects of doxepin, imipramine, and fluoxetine on the excitatory amino acid transporter type 3 (EAAT3). METHODS: EAAT3 was expressed in Xenopus oocytes by injection of EAAT3 mRNA. Membrane currents were recorded after application of L-glutamate (30 µM) in the presence or absence of various concentrations of doxepin, imipramine, and fluoxetine. To study the effects of protein kinase C (PKC) activation on EAAT3 activity, oocytes were pre-incubated with phorbol 12-myristate-13-acetate (PMA) before application of imipramine and doxepin. RESULTS: Doxepin at 0.063-1.58 µM significantly decreased EAAT3 activity. Imipramine reduced EAAT3 activity in a concentration-dependent manner at 0.16-0.95 µM. However, fluoxetine did not affect EAAT3 activity, and PMA increased EAAT3 activity. At 0.32 µM, imipramine caused an equivalent decrease in EAAT3 activity in the presence or absence of PMA. However, 0.79 µM doxepin did not abolish the enhancement of EAAT3 activity by PMA. CONCLUSIONS: We showed that doxepin and imipramine, but not fluoxetine, inhibited EAAT3 activity at clinically relevant concentrations. This reveals a novel mechanism of action for doxepin and imipramine; that they increase glutamatergic neurotransmission. PKC may be involved in the effects of doxepin on EAAT3, but is not involved in the effects of imipramine at the concentrations studied.


Assuntos
Doxepina/farmacologia , Transportador 3 de Aminoácido Excitatório/antagonistas & inibidores , Fluoxetina/farmacologia , Imipramina/farmacologia , Animais , Antidepressivos/administração & dosagem , Antidepressivos/farmacologia , Relação Dose-Resposta a Droga , Doxepina/administração & dosagem , Feminino , Fluoxetina/administração & dosagem , Ácido Glutâmico/metabolismo , Imipramina/administração & dosagem , Oócitos/efeitos dos fármacos , Oócitos/metabolismo , Proteína Quinase C/metabolismo , RNA Mensageiro/metabolismo , Ratos , Acetato de Tetradecanoilforbol/farmacologia , Xenopus laevis
13.
Drug Deliv ; 22(6): 869-76, 2015.
Artigo em Inglês | MEDLINE | ID: mdl-24670096

RESUMO

Tricyclic antidepressants, as doxepin hydrochloride (DH), may have analgesic local effect due to its biochemical mechanism of action. Delivery of DH directly to the oral cavity could be an interesting alternative for toothache due to its analgesic local effect. One problem associated with the mucosal administration routes is the short residence time of the dosage form on the mucosal membranes. In this sense, we have developed new doxepin mucoadhesive films able of reducing pain and increasing the effectiveness of treatment. For this purpose, we tested three different polymers: chitosan, sodium hydroxypropylmethylcellulose (HPMC) and sodium carboxymethylcellulose (SCMC) in film elaboration. The results obtained show that all films are hydrophilic matrices that absorb water when placed in an aqueous media. All the films hydrated very quickly, reaching high percentage of swelling after just few minutes (5 min for SCMC, 2 min for HPMC and 30 min for chitosan). Moreover, the SCMC and HPMC films were dissolved whereas chitosan was not dissolved. Dissolution also leads to viscous liquids with a higher retention time over mucosal surfaces what may lead to adhesive interactions. In vitro permeation studies showed that for all the formulations studied, SCMC (19.91%), HPMC (69.5%) and chitosan (24.17%), the percentage of drug permeated increased compared to the drug solution (8.26%). Specifically the HPMC film presents greater amounts of doxepin permeated (49.27 ± 4.47 µg/cm(2)).


Assuntos
Antidepressivos Tricíclicos/administração & dosagem , Carboximetilcelulose Sódica/química , Quitosana/química , Doxepina/administração & dosagem , Derivados da Hipromelose/química , Odontalgia/tratamento farmacológico , Adesividade , Administração Bucal , Varredura Diferencial de Calorimetria , Química Farmacêutica , Liberação Controlada de Fármacos , Concentração de Íons de Hidrogênio
14.
Int J Pharm ; 477(1-2): 650-4, 2014 Dec 30.
Artigo em Inglês | MEDLINE | ID: mdl-25445535

RESUMO

According to previous studies reporting the anesthetic/analgesic action of oral topical doxepin administration, this study evaluated a model of buccal permeation to determine the depth of delivery of doxepin into excised porcine buccal mucosa following topical application of a saturated aqueous doxepin solution. Buccal mucosa permeation studies were performed using Franz diffusion cells. Cumulative amounts of doxepin permeated were plotted as a function of time. Kinetic permeation parameters as flux (Js), lag time (Tl) and permeability coefficient (Kp) were calculated. Theoretical human plasmatic steady-state doxepin concentration and drug retained in the tissue were also determined in order to evaluate its potential therapeutic use, central or peripheral. Finally, a histological evaluation of the buccal mucosa was performed to test potential damage due to the permeation phenomenon. Obtained results showed a poor aqueous doxepin permeation through buccal mucosa membrane (median parameters Js=34.79 µg/h, Kp=0.49×10(-3)cm/h and Tl=2.8h). Predicted doxepin plasma concentrations would reach 46 ng/mL, far from the required to have central nervous system activity as tricyclic agent. However, median doxepin amount remaining in the mucosa membrane was 0.24 µg/cm(2)/µg tissue, which evidenced a reservoir function of the buccal mucosa. Histologically, no structural damage was observed in the tissues. This study lays the foundation for further research within this area with a view to potentially adopting alternative strategies for enhanced buccal absorption of doxepin in clinical practice.


Assuntos
Analgésicos/administração & dosagem , Doxepina/administração & dosagem , Mucosa Bucal/efeitos dos fármacos , Absorção pela Mucosa Oral , Administração Bucal , Analgésicos/farmacocinética , Analgésicos/toxicidade , Animais , Doxepina/farmacocinética , Doxepina/toxicidade , Feminino , Técnicas In Vitro , Mucosa Bucal/metabolismo , Mucosa Bucal/patologia , Absorção pela Mucosa Oral/efeitos dos fármacos , Permeabilidade , Valor Preditivo dos Testes , Suínos , Distribuição Tecidual
15.
J Clin Oncol ; 32(15): 1571-7, 2014 May 20.
Artigo em Inglês | MEDLINE | ID: mdl-24733799

RESUMO

PURPOSE: Painful oral mucositis (OM) is a significant toxicity during radiotherapy for head and neck cancers. The aim of this randomized, double-blind, placebo-controlled trial was to test the efficacy of doxepin hydrochloride in the reduction of radiotherapy-induced OM pain. PATIENTS AND METHODS: In all, 155 patients were randomly allocated to a doxepin oral rinse or a placebo for the treatment of radiotherapy-related OM pain. Patients received a single dose of doxepin or placebo on day 1 and then crossed over to receive the opposite agent on a subsequent day. Pain questionnaires were administered at baseline and at 5, 15, 30, 60, 120, and 240 minutes. Patients were then given the option to continue doxepin. The primary end point was pain reduction as measured by the area under the curve (AUC) of the pain scale using data from day 1. RESULTS: Primary end point analysis revealed that the AUC for mouth and throat pain reduction was greater for doxepin (-9.1) than for placebo (-4.7; P < .001). Crossover analysis of patients completing both phases confirmed that patients experienced greater mouth and throat pain reduction with doxepin (intrapatient changes of 4.1 for doxepin-placebo arm and -2.8 for placebo-doxepin arm; P < .001). Doxepin was associated with more stinging or burning, unpleasant taste, and greater drowsiness than the placebo rinse. More patients receiving doxepin expressed a desire to continue treatment than did patients with placebo after completion of each of the randomized phases of the study. CONCLUSION: A doxepin rinse diminishes OM pain. Further studies are warranted to determine its role in the management of OM.


Assuntos
Dor Aguda/tratamento farmacológico , Analgésicos/administração & dosagem , Quimiorradioterapia/efeitos adversos , Irradiação Craniana/efeitos adversos , Doxepina/administração & dosagem , Dor Facial/tratamento farmacológico , Neoplasias de Cabeça e Pescoço/radioterapia , Estomatite/tratamento farmacológico , Dor Aguda/induzido quimicamente , Dor Aguda/diagnóstico , Adulto , Idoso , Idoso de 80 Anos ou mais , Analgésicos/efeitos adversos , Área Sob a Curva , Estudos Cross-Over , Método Duplo-Cego , Doxepina/efeitos adversos , Dor Facial/induzido quimicamente , Dor Facial/diagnóstico , Feminino , Neoplasias de Cabeça e Pescoço/tratamento farmacológico , Humanos , Masculino , Pessoa de Meia-Idade , Antissépticos Bucais , Medição da Dor , Valor Preditivo dos Testes , Estomatite/induzido quimicamente , Estomatite/diagnóstico , Inquéritos e Questionários , Fatores de Tempo , Resultado do Tratamento , Estados Unidos
16.
Int Clin Psychopharmacol ; 29(4): 206-11, 2014 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-24374906

RESUMO

Valproic acid and the antidepressants doxepin and venlafaxine are frequently used psychotropic drugs. In the literature, an influence of valproic acid on serum levels of antidepressants has been described, although studies have focused on amitriptyline. The authors assessed their therapeutic drug monitoring (TDM) database for patients receiving a combination of doxepin or venlafaxine and valproic acid and compared these samples with matched controls without valproic acid comedication in terms of the serum concentration of antidepressants. The mean dose-corrected serum concentration of doxepin+N-doxepin in 16 patients who received valproic acid comedication was higher (2.171±1.482 ng/ml/mg) than that in the matched controls (0.971±0.857 ng/ml/mg, P<0.003). We also found a significant correlation between valproic acid serum level and dose-corrected doxepin+N-doxepin serum level (Spearman's ρ r=0.602, P<0.014). The mean dose-corrected serum level of venlafaxine+O-desmethylvenlafaxine in 41 patients who received valproic acid comedication did not differ significantly from that of the matched controls (P<0.089), but there was a significant difference between both groups in the dose-corrected serum level of O-desmethylvenlafaxine (1.403±0.665 vs. 1.102±0.444, P<0.017). As a consequence, if a combination of valproic acid with doxepin or venlafaxine is administered, cautious dosing is advisable and TDM should be performed.


Assuntos
Antidepressivos/uso terapêutico , Cicloexanóis/uso terapêutico , Depressão/tratamento farmacológico , Doxepina/uso terapêutico , Monitoramento de Medicamentos , Ácido Valproico/uso terapêutico , Adulto , Idoso , Antidepressivos/administração & dosagem , Antidepressivos/efeitos adversos , Antidepressivos/farmacocinética , Biotransformação/efeitos dos fármacos , Cicloexanóis/administração & dosagem , Cicloexanóis/efeitos adversos , Cicloexanóis/farmacocinética , Depressão/sangue , Relação Dose-Resposta a Droga , Doxepina/administração & dosagem , Doxepina/efeitos adversos , Doxepina/farmacocinética , Interações Medicamentosas , Quimioterapia Combinada/efeitos adversos , Feminino , GABAérgicos/administração & dosagem , GABAérgicos/efeitos adversos , GABAérgicos/farmacocinética , GABAérgicos/uso terapêutico , Alemanha , Antagonistas dos Receptores Histamínicos/administração & dosagem , Antagonistas dos Receptores Histamínicos/efeitos adversos , Antagonistas dos Receptores Histamínicos/farmacocinética , Antagonistas dos Receptores Histamínicos/uso terapêutico , Hospitais Universitários , Humanos , Masculino , Pessoa de Meia-Idade , Estudos Retrospectivos , Inibidores Seletivos de Recaptação de Serotonina/administração & dosagem , Inibidores Seletivos de Recaptação de Serotonina/efeitos adversos , Inibidores Seletivos de Recaptação de Serotonina/farmacocinética , Inibidores Seletivos de Recaptação de Serotonina/uso terapêutico , Ácido Valproico/administração & dosagem , Ácido Valproico/efeitos adversos , Ácido Valproico/farmacocinética , Cloridrato de Venlafaxina
17.
Ars pharm ; 54(2): 39-43[2], abr.-jun. 2013. tab, graf
Artigo em Espanhol | IBECS | ID: ibc-129245

RESUMO

Objetivo: El objetivo de este estudio es el diseño de un parche bucoadhesivo para la administración transbucal de clorhidrato de doxepina utilizando diferentes polímeros así como la caracterización de dichos sistemas en cuanto al análisis calorimétrico y la capacidad de hinchamiento. Materiales y métodos: Se ha utilizado clorhidrato de doxepina y diferentes polímeros, carboximetilcelulosa sódica, hidroxipropilmetilcelulosa y chitosan. La calorimetría diferencial de barrido (DSC) se ha realizado en un dispositivo Mettler FP 80 equipado con un horno FP 85 y la capacidad de hinchamiento utilizando placas de agar. Resultados: Se obtienen termogramas de los parches y las mezclas físicas donde se observan transiciones endotérmicas entre 30 y 120º C y el pico endotérmico del principio activo en las mezclas físicas binarias. La entalpía de deshidratación es similar en los polímeros de carboximetilcelulosa sódica y chitosan (281 J/g) siendo menor en la película de hidroxipropilmetilcelulosa (251 J/g), al igual que el porcentaje de hidratación donde se demuestra que los parches elaborados con hidroxipropilmetilcelulosa presenta menor tendencia a captar agua (55,91 %) frente al 67,04 % y 67,30 % de la carboximetilcelulosa sódica y chitosan, respectivamente. Conclusión: Los resultados obtenidos muestran que existe compatibilidad entre los componentes de la formulación y los datos de entalpía se correlacionan con los datos obtenidos en el ensayo de hinchamiento (AU)


Aim: The aim of this study is to design a bucoadhesive patch for the transbuccal administration of doxepin hydrochloride using different polymers as well as the characterization of these systems for calorimetric analysis and the swelling capacity. Materials and methods: Doxepin hydrochloride was used as well as various polymers; carboxymethylcellulose sodium, hydroxypropylmethyl cellulose and chitosan. Differential scanning calorimetry (DSC) was carried out using a Mettler FP 80 device equipped with a FP 85 oven and the swelling capacity using agar plates. Results: Thermograms obtained patches and physical mixtures where there are endothermic transitions between 30 and 120º C and the endothermic peak of the active principle in binary physical mixtures. Dehydration enthalpy is similar in polymers of carboxymethylcellulose sodium and chitosan (281 J/g), the film having less hydroxypropylmethylcellulose (251 J/g), the percentage of moisture shows that the patches prepared with hydroxypropylmethylcellulose have less tendency to collect water (55.91 %) compared to 67.04 % and 67.30 % with sodium carboxymethylcellulose and chitosan, respectively. Conclusion: The results show that there is compatibility between the components of the formulation and the enthalpy data correlate with the data obtained in the swelling test (AU)


Assuntos
Humanos , Adesivo Transdérmico , Administração Bucal , Doxepina/administração & dosagem , Quitosana/administração & dosagem , Calorimetria/métodos , Inflamação/induzido quimicamente , Carboximetilcelulose Sódica/administração & dosagem
18.
Colloids Surf B Biointerfaces ; 103: 558-65, 2013 Mar 01.
Artigo em Inglês | MEDLINE | ID: mdl-23261580

RESUMO

Antidepressants have been considered by their analgesic activity in numerous studies, and specifically tricyclic antidepressants to possess the greatest efficacy. Imipramine and doxepin have been reported to exhibit local anaesthetic properties. In order to investigate their cutaneous analgesic effect after topical application a nanoemulsion vehicle was developed. This nanoemulsion is composed of propilenglicol, Transcutol, water, Labrasol, Plurol Oleique, isostearyl isostearate, oleic acid, and d-limonene. The final concentration of imipramine or doxepin in the nanoemulsion system was 3% (w/w). The nanoemulsions were characterized by pH, viscosity, droplet size, polydispersity index and finally, a morphological and structural examination was carried out by using transmission electron microscopy. Furthermore, the present work also reports stability studies on the nanoemulsion formulations to evaluate the integrity of the formulation; these indicate that formulations are stable for a period of three months. Moreover ex vivo studies were performed to evaluate permeation behaviour through human skin and predict plasma concentrations concluding that topically applied imipramine and doxepin loaded nanoemulsions were safe for a local effect. Similarly, the in vivo analgesic and anti-allodynic activity in rats was evaluated being stronger for the doxepin loaded nanoemulsion. This study demonstrated that nanoemulsion containing doxepin could be promising as an alternative analgesic therapy with a potential clinical application.


Assuntos
Analgésicos/uso terapêutico , Doxepina/uso terapêutico , Sistemas de Liberação de Medicamentos , Hiperalgesia/tratamento farmacológico , Imipramina/uso terapêutico , Nanopartículas/química , Óleos/química , Administração Cutânea , Analgésicos/administração & dosagem , Analgésicos/farmacologia , Animais , Área Sob a Curva , Química Farmacêutica , Doxepina/administração & dosagem , Doxepina/farmacologia , Emulsões , Estudos de Avaliação como Assunto , Humanos , Imipramina/administração & dosagem , Imipramina/farmacologia , Técnicas In Vitro , Masculino , Nanopartículas/ultraestrutura , Permeabilidade/efeitos dos fármacos , Transição de Fase/efeitos dos fármacos , Ratos , Ratos Sprague-Dawley , Absorção Cutânea/efeitos dos fármacos , Água/química
20.
Sleep Med ; 13(2): 133-8, 2012 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-22197474

RESUMO

INTRODUCTION: The efficacy and safety of doxepin (DXP), a histamine H(1) receptor antagonist, was evaluated in elderly adults with sleep maintenance insomnia. METHODS: This was a randomized, double-blind, placebo-controlled outpatient trial. Elderly adults meeting DSM-IV-TR criteria for primary insomnia were randomized to four weeks of nightly treatment with either DXP 6 mg (N=130) or placebo (PBO; N=124). Efficacy was assessed using patient self-report instruments and clinician ratings. Patient-reported endpoints included subjective total sleep time (sTST), subjective wake after sleep onset (sWASO), latency to sleep onset (LSO), sleep quality, and a Patient Global Impression scale (PGI). The primary endpoint was sTST at week 1. RESULTS: DXP 6 mg produced significantly more sTST and less sWASO at week 1 (both p-values <0.0001) than PBO. These significant improvements versus placebo were maintained at weeks 2-4 (all p-values <0.05). There were no significant differences in LSO for DXP 6 mg versus PBO. DXP 6 mg significantly improved sleep quality (weeks 1, 3, and 4, p<0.05) and several outcome-related parameters, including several items on the PGI, the severity and improvement items of the Clinician Global Impression scale (CGI; weeks 1 and 2) and the Insomnia Severity Index (ISI; weeks 1-4), all versus PBO. There were no reports of anticholinergic effects (e.g., dry mouth) or memory impairment. The safety profile of DXP 6 mg was comparable to that of PBO. CONCLUSIONS: In elderly adults with insomnia, DXP 6 mg produced significant improvements in sleep maintenance, sleep duration, and sleep quality endpoints that were sustained throughout the trial. These data suggest that DXP 6 mg is effective for treating sleep maintenance insomnia and is well-tolerated in elderly adults with chronic primary insomnia.


Assuntos
Doxepina/administração & dosagem , Antagonistas dos Receptores Histamínicos H1/administração & dosagem , Distúrbios do Início e da Manutenção do Sono/tratamento farmacológico , Sono/efeitos dos fármacos , Idoso , Idoso de 80 Anos ou mais , Doença Crônica , Doxepina/efeitos adversos , Feminino , Antagonistas dos Receptores Histamínicos H1/efeitos adversos , Humanos , Masculino , Pessoa de Meia-Idade , Pacientes Ambulatoriais , Placebos , Resultado do Tratamento
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...